Amgen Q3 Revenue Grows 8%, Raises 2026 Guidance Amid Biologics Portfolio Momentum

The Quick Take

• Amgen (AMGN) reported 8% revenue growth in Q3 2026 and raised its full-year 2026 guidance, reinforcing confidence in its diverse biologics portfolio.
• Growth was driven by key franchise products — including MariTide (obesity/metabolic) ramp-up and established inflammation/oncology brands.
• The guidance raise signals management confidence in sustained demand and manufacturing capacity, a key concern given the competitive GLP-1 market.

Amgen's 8% Q3 revenue growth and guidance raise represent a meaningful positive inflection for the large-cap biopharma sector. The company has been investing heavily in its MariTide obesity drug candidate as a potential challenger to Novo Nordisk's Wegovy and Eli Lilly's Zepbound — the most competitive segment in pharma. While MariTide is earlier in its commercial ramp, the core portfolio of ENBREL, Prolia, and Repatha continues generating substantial cash flows that fund pipeline development.

The guidance raise is particularly significant for investor confidence. Amgen's initial 2026 guidance was conservative given uncertainty around Medicare drug pricing negotiations under the IRA and competitive biosimilar pressure on legacy products. By lifting the full-year outlook mid-Q3, management signals that volume and pricing execution has outpaced these headwinds — a constructive signal for the broader large-cap biopharma sector.

For Asia and India-listed pharma investors, Amgen's performance is a bellwether for the global biologics sector. Rising Amgen demand for active pharmaceutical ingredients and contract manufacturing may benefit Indian CDMO (contract development and manufacturing) companies such as Divi's Laboratories and Syngene International. Watch Amgen's biosimilar pipeline progress and MariTide Phase 3 readouts as near-term catalysts.

Synthesized from 1 source.